Research programme: polyclonal immunoglobulins - Fab-entech

Drug Profile

Research programme: polyclonal immunoglobulins - Fab-entech

Alternative Names: F(ab')2

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Fab entech
  • Class Antibodies; Immunoglobulins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Drug abuse

Highest Development Phases

  • No development reported Crimean-Congo haemorrhagic fever virus infections; Drug abuse; Ebola virus infections; Lassa fever; Nipah virus infections; Severe acute respiratory syndrome

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Lassa-fever in France (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for research development in Drug-abuse in France (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for research development in Ebola-virus-infections in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top